Source: United Kingdom – Government Statements
SPC change – Credelio Chewable Tablets for Dogs
Change to the information provided on adverse events in the Summary of Product Characteristics for Credelio 56mg/ 112mg/ 225mg/ 450mg/ 900mg Chewable Tablets for Dogs
Following monitoring of pharmacovigilance data, the Summary of Product Characteristics (SPCs) for Credelio 56 mg / 112 mg / 225 mg / 450 mg / 900 mg Chewable Tablets for Dogs have been updated:
Pruritus, bloody diarrhoea, urinary incontinence, inappropriate urination, polyuria and polydipsia can occur very rarely following the administration of the veterinary medicinal product.
Any veterinary medicinal product which is authorised for marketing in the United Kingdom will have its Summary of Product Characteristics (SPC) available on our Product Information Database.
No medicine is 100% risk free, the SPC includes information on what adverse events have been known to occur following administration of a particular product, these can be found in either section Adverse events (3.6) or Adverse reactions (4.6).
All updates to SPCs other than template changes, are published in the medicine updates section of VMD Connect.